XOMA Corp (XOMA) Reports Mixed Financial Results for Q4 and Full Year 2023 [Yahoo! Finance]
Kinnate Biopharma Inc. (KNTE)
Company Research
Source: Yahoo! Finance
Net Loss: The company reported a net loss of $20.1 million for Q4 and $40.8 million for the full year. Cash Position: As of December 31, 2023, XOMA had cash and cash equivalents of $159.6 million. Impairment Charges: XOMA recorded $15.8 million in impairment charges due to discontinued operations and terminated agreements. Upcoming Events: Potential FDA action dates for tovorafenib and arimoclomol NDAs in 2024 could impact future revenues. Stock Repurchase Program: XOMA announced a stock repurchase program of up to $50 million through January 2027. Acquisitions: XOMA acquired economic interest in DSUVIA and announced the intention to acquire Kinnate Biopharma. Warning! GuruFocus has detected 6 Warning Signs with XOMA. On March 8, 2024, XOMA Corp ( NASDAQ:XOMA ) released its 8-K filing , detailing the financial results for the fourth quarter and full year of 2023. XOMA, a biotechnology royalty aggregator, is known for acquiring future economic rights associated with pre-
Show less
Read more
Impact Snapshot
Event Time:
KNTE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KNTE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KNTE alerts
High impacting Kinnate Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
KNTE
News
- SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates KNTE, DOOR, HMSTGlobeNewswire
- KINNATE BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kinnate Biopharma Inc. - KNTEBusiness Wire
- SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - EVBG, TAST, ZFOX, KNTEPR Newswire
- STOCKHOLDER INVESTIGATION: The M&A Class Action Firm Continues Investigating the Merger - KNTE, INBX, KAMNAccesswire
- SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Acquisition of Kinnate Biopharma Inc. by XOMA CorporationGlobeNewswire
KNTE
Earnings
- 11/9/23 - Beat
KNTE
Sec Filings
- 4/3/24 - Form S-8
- 4/3/24 - Form S-8
- 4/3/24 - Form S-8
- KNTE's page on the SEC website